论文部分内容阅读
目的 探讨自行设计的内皮前体细胞(EPCs)释放系统体外释放EPCs的可行性和条件.材料与方法采用自行设计的EPCs释放系统(国家专利号:ZL2006200406232),将由人体外周静脉血液(40 ml)提取培养的EPCs,在不同条件下(扩张压力和注射压力)以Annexin V及PI染色测量细胞数量和存活率.结果 EPCs释放系统在体外可以有效释放EPCs,数据显示充盈压<3 atm及细胞悬液的释放流率<0.3 ml/s时,释放后的EPCs的数量、细胞活性以及细胞凋亡和坏死与释放前体外相比,差异无统计学意义;释放流率0.2 ml/s及压力2.5 atm为峰值,EPCs的存活率最高.结论 在一定释放压力和流率下,EPCs释放系统可以有效释放EPCs,为血管狭窄及再狭窄治疗提供一种新器械和思路.“,”Objective To explore the feasibility and optimize the working parameters of seff-designed endothelial progenitor cells release system (EPCs-RS) when releasing endothelial progenitor cells (EPCs) in vitro. Materials and Methods EPCs were isolated and cultured from 40 ml human peripheral blood. EPCs were released with the EPCs-RS (Patent No. ZL2006200406232) under a different series of working pressure and releasing speed, then the cell survival rates were tested by Annexin V and PI stain. Results The EPCs-RS can release EPCs effectively. A series data demonstrated there was no variation of cell survival rate before and after releasing cells under a pressure less than 3 atm and a speed less than 0.3 ml/s. It also showed that EPCs could remain with the highest activity when released at the pressure of 2.5 atm and the releasing speed of 0.2 ml/s. Conclusion Under certain working pressure and releasing rate, the EPCs-RS can release EPCs effectively. This system may have been a novel device and provided a new method in treating peripheral vascular occlusive disease and preventing restenosis after PTA therapy.